Fertility-Sparing Treatment of Endometrial Cancer and Atypical Endometrial Hyperplasia by Molecular Classification: A Systematic Review and Meta-Analysis Accounting for Outcome-Assessment Timing and Follow-Up Duration

Short summary

Fertility-sparing treatment (FST) complete response rates vary by endometrial cancer molecular subtype, with POLE and NSMP subtypes showing 85% best CR, MMRd 71%, and p53abn showing variable response. Recurrence rates after CR were 34% for MMRd and 30% for NSMP. Subtype comparisons are sensitive to outcome-assessment timing and follow-up duration.

AI-generated from the title and abstract; the full text is not read.